Taiwan Liposome Company

A Phase 2, Open Label, Pharmacokinetic (PK) Study of TLC599 in Subjects With Osteoarthritis of the Knee

Role: lead

Extended and Controlled Release Liposomal Formulated Dexamethasone for Chronic Knee OA Pain

Role: lead

Phase IIa, Randomized, Double Blinded, Placebo Controlled, Dose Finding Study for TLC599 in OA Patients

Role: lead

Phase 2/3 Study of TLC590 for Postsurgical Pain Management

Role: lead

Single-Dose Administration Trial of TLC599 in Osteoarthritis of the Knee

Role: lead

TLC399 (ProDex) in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO)

Role: lead

Phase 1 Open-label Study to Evaluate Efficacy and Tolerability of TLC399 in Patients With Macular Edema Due to RVO

Role: lead

The Safety, Tolerability, and Pharmacokinetics of Inhaled TLC19 in Healthy Volunteers

Role: lead

Dose-escalation Study of Intravenous Liposomal Vinorelbine Tartrate Injection in Patients With Advanced Malignancy

Role: lead

Phase I/II Dose-escalation Study to Evaluate Safety, PK and Efficacy of TLC590 for Postsurgical Pain Management

Role: lead

Ampholipad Real-World Data in Taiwan

Role: lead

A Study to Evaluate Safety, PK, Efficacy of TLC590 for Postsurgical Pain Management Following Bunionectomy

Role: lead

Phase I Study of Intravenous Lipotecan® (TLC388 HCl for Injection) in Patients With Advanced Solid Tumors

Role: lead

Efficacy and Safety Study of TLC388 to Advanced Hepatocellular Carcinoma

Role: lead

Lipotecan Based Concurrent Chemoradiotherapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis

Role: lead

A Dose-escalation Study of Lipotecan® Plus Radiotherapy in Locally Advanced Hepatocellular Carcinoma

Role: lead

A Phase II Study to Evaluate the Efficacy and Safety of TLC388 in Advanced/Metastatic RCC Patients

Role: lead

An Bioequivalence Study to Compare Two 2 mg/ml Liposomal Amphotericin B Injections in Healthy Subjects

Role: lead